Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2009-05-14

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm801640kPMID 19309154PMCID PMC2832307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The bacterial and mitochondrial ribosomal A-site molecular switches possess different conformational substates

  2008cited by this paper
• A meta‐analysis of nonsense mutations causing human genetic disease

  2008cited by this paper
• Combined Chemical‐Enzymatic Assembly of Aminoglycoside Derivatives with N‐1‐AHB Side Chain

  2008cited by this paper
• Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases.

  2008cited by this paper
• Mitochondrial deafness alleles confer misreading of the genetic code

  2008cited by this paper
• Differential Selectivity of Natural and Synthetic Aminoglycosides towards the Eukaryotic and Prokaryotic Decoding A Sites

  2007cited by this paper
• In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome

  2007cited by this paper
• Crystal structure of the bacterial ribosomal decoding site complexed with amikacin containing the γ-amino-α-hydroxybutyryl (haba) group

  2006cited by this paper
• Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model

  2006cited by this paper
• Aspirin to prevent gentamicin-induced hearing loss.

  2006cited by this paper
• Crystal structure of the bacterial ribosomal decoding site complexed with amikacin containing the gamma-amino-alpha-hydroxybutyryl (haba) group.

  2006cited by this paper
• Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.

  2006cited by this paper
• Dual effect of synthetic aminoglycosides: antibacterial activity against Bacillus anthracis and inhibition of anthrax lethal factor.

  2005cited by this paper
• Defining the basis for the specificity of aminoglycoside-rRNA recognition: a comparative study of drug binding to the A sites of Escherichia coli and human rRNA.

  2005cited by this paper
• Effects of the antibiotic gentamicin on nicotinic acetylcholine receptors.

  2005cited by this paper
• Pharmacological Suppression of Premature Stop Mutations that Cause Genetic Diseases

  2005cited by this paper
• Pharmacologic therapy for stop mutations: how much CFTR activity is enough?

  2004cited by this paper
• The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography.

  2003cited by this paper
• Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results.

  2003cited by this paper
• AMINOGLYCOSIDE ANTIBIOTICS

  2003cited by this paper
• Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.

  2003cited by this paper
• Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis.

  2002cited by this paper
• Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene

  2002cited by this paper
• Structural basis for selectivity and toxicity of ribosomal antibiotics

  2001cited by this paper
• Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations

  2001cited by this paper
• Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system.

  2000cited by this paper
• Sequence specificity of aminoglycoside‐induced stop codon readthrough: Potential implications for treatment of Duchenne muscular dystrophy

  2000cited by this paper
• Block of the alpha9 nicotinic receptor by ototoxic aminoglycosides.

  2000cited by this paper
• Aminoglycoside Antibiotics

  2000cited by this paper
• Block of the α9 nicotinic receptor by ototoxic aminoglycosides

  2000cited by this paper
• Correction of genetic disease by making sense from nonsense.

  1999cited by this paper
• Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice.

  1999cited by this paper
• Design and Synthesis of New Aminoglycoside Antibiotics Containing Neamine as an Optimal Core Structure: Correlation of Antibiotic Activity with in Vitro Inhibition of Translation

  1999cited by this paper
• Semisynthetic aminoglycoside antibiotics: Development and enzymatic modifications

  1999cited by this paper
• Probing the Specificity of Aminoglycoside−Ribosomal RNA Interactions with Designed Synthetic Analogs

  1998cited by this paper
• A dual-luciferase reporter system for studying recoding signals.

  1998cited by this paper
• Potentiation of aminoglycoside-induced neuromuscular blockade by protons in vitro and in vivo.

  1987cited by this paper
• Calculating thermodynamic data for transitions of any molecularity from equilibrium melting curves

  1987cited by this paper
• Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin.

  1985cited by this paper
• Control of site-specific substitution of aminoglycosides by transition metal cations

  1981cited by this paper
• Comparison of neuromuscular effects and acute toxicity of some aminoglycoside antibiotics.

  1978cited by this paper
• The neuromuscular blocking activity of aminodeoxykanamycin as compared with that of other aminoglycoside antibiotics.

  1977cited by this paper
• Aminoglycoside antibiotics. VII. Acute toxicity of aminoglycoside antibiotics.

  1974cited by this paper
• Ototoxicity studies with BB-K8, a new semisynthetic aminoglycoside antibiotic.

  1973cited by this paper
• Statistical thermodynamics of nucleic acid melting transitions with coupled binding equilibria

  1971cited by this paper
• The neuromuscular blocking action of gentamicin.

  1969cited by this paper
• A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS

  1938cited by this paper

• Identification of Novel Small Molecule Compounds with Readthrough Activity in Nagashima-Type Palmoplantar Keratosis

  2026cites this paper
• Translational readthrough using TRIDs - Achievements and challenges for the treatment of inherited retinal disorders.

  2026cites this paper
• A Translational Roadmap for Neurological Nonsense Mutation Disorders

  2026cites this paper
• Design, Synthesis, and Screening of an RNA Optimized Fluorinated Fragment Library.

  2025cites this paper
• Recovery of α-L-fucosidase in fucosidosis nonsense variants by readthrough stimulation and release factor degradation

  2025cites this paper
• Readthrough Activators and Nonsense-Mediated mRNA Decay Inhibitor Molecules: Real Potential in Many Genetic Diseases Harboring Premature Termination Codons

  2024cites this paper
• Precision medicine advances in cystic fibrosis: Exploring genetic pathways for targeted therapies.

  2024cites this paper
• Mechanisms and Delivery of tRNA Therapeutics

  2024cites this paper
• Balancing Nonsense Mutation Readthrough and Toxicity of Designer Aminoglycosides for Treatment of Genetic Diseases

  2023cites this paper
• Evaluation of Novel Enhancer Compounds in Gentamicin-Mediated Readthrough of Nonsense Mutations in Rett Syndrome

  2023cites this paper
• Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development

  2023influential citation
• Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond

  2023cites this paper
• Case report: Compound heterozygous nonsense PCDH15 variant and a novel deep‐intronic variant in a Chinese child with profound hearing loss

  2023cites this paper
• Recoding of Nonsense Mutation as a Pharmacological Strategy

  2023cites this paper
• Readthrough compounds for nonsense mutations: bridging the translational gap.

  2023cites this paper
• Regulatory RNAs in the Molecular Pathology of Neoplasia

  2022cites this paper
• High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing

  2022cites this paper
• Nonsense Suppression Therapy: An Emerging Treatment for Hereditary Skin Diseases

  2022cites this paper
• Polyfunctional Drugs: Search, Development, Use in Medical Practice, and Environmental Aspects of Preparation and Application (A Review)

  2022cites this paper
• A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion

  2021cites this paper
• Inherited retinal diseases: Linking genes, disease-causing variants, and relevant therapeutic modalities.

  2021cites this paper
• Antisense Oligonucleotide Therapy to Correct CFTR Function in People with Cystic Fibrosis

  2021cites this paper
• Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets.

  2021cites this paper
• MPS I: Early diagnosis, bone disease and treatment, where are we now?

  2021cites this paper
• Cystic fibrosis

  2021cites this paper
• Read-through approach for stop mutations in Duchenne muscular dystrophy. An update

  2021cites this paper
• Nonsense suppression therapies in human genetic diseases

  2021cites this paper
• Deciphering the molecular mechanism of stop codon readthrough

  2020cites this paper
• Sensing through Non-Sensing Ocular Ion Channels

  2020cites this paper
• Usher syndrome: clinical features, molecular genetics and advancing therapeutics

  2020cites this paper
• Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning

  2020cites this paper
• A Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome

  2020cites this paper
• STATE OF THE ART Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

  2020cites this paper
• Natural products targeting the elongation phase of eukaryotic protein biosynthesis.

  2020cites this paper
• Translational read-through inducing drugs for the treatment of inherited 1 retinal dystrophies

  2020cites this paper
• Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia

  2020cites this paper
• Pharmacological readthrough of R294X Mecp2 in a novel mouse model of Rett Syndrome.

  2020cites this paper
• Pharmacological approaches for targeting cystic fibrosis nonsense mutations.

  2020cites this paper
• Development of 6′-N-Acylated Isepamicin Analogs with Improved Antibacterial Activity against Isepamicin-Resistant Pathogens

  2020cites this paper
• Translational readthrough inducing drugs for the treatment of inherited retinal dystrophies

  2020cites this paper
• Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes

  2020cites this paper
• Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches

  2020cites this paper
• Aptamer protective groups tolerate different reagents and reactions for regioselective modification of neomycin B.

  2020cites this paper
• Serum starvation enhances nonsense mutation readthrough

  2019cites this paper
• New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.

  2019cites this paper
• Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges

  2019cites this paper
• Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders

  2019cites this paper
• Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine

  2019cites this paper
• Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

  2019cites this paper
• A no-nonsense approach to hereditary kidney disease

  2019cites this paper
• Crystal structure of GenB1 from Micromonospora echinospora in complex with PLP (internal aldimine)

  2019cites this paper
• Emerging pharmacotherapies in cystic fibrosis

  2018cites this paper
• p.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS‐7 cells

  2018cites this paper
• Secretion of wild‐type factor IX upon readthrough over F9 pre‐peptide nonsense mutations causing hemophilia B

  2018cites this paper
• Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps

  2018cites this paper
• Comprehensive review of chemical strategies for the preparation of new aminoglycosides and their biological activities.

  2018cites this paper
• Complete reconstitution of the diverse pathways of gentamicin B biosynthesis

  2018cites this paper
• Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons

  2018cites this paper
• Aminoglycoside-Induced Nephrotoxicity

  2018cites this paper
• The aminoglycoside geneticin permits translational readthrough of the CTNS W138X nonsense mutation in fibroblasts from patients with nephropathic cystinosis

  2018cites this paper
• Investigating the pathophysiology of KCNJ13 and USH2A retinopathies using zebrafish models

  2018cites this paper
• Structure‐Based Design of a Eukaryote‐Selective Antiprotozoal Fluorinated Aminoglycoside

  2018cites this paper
• Cilia - The sensory antennae in the eye.

  2017cites this paper
• Title : Mechanism and evidence of nonsense suppression therapy for genetic eye 1 disorders 2 3

  2017cites this paper
• Toward inclusive therapy with CFTR modulators: Progress and challenges

  2017cites this paper
• Mechanism and evidence of nonsense suppression therapy for genetic eye disorders

  2017cites this paper
• Overarching Concepts and Mechanisms Affecting Phenotypes of Ocular Genetic Conditions

  2017cites this paper
• Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells

  2017cites this paper
• Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.

  2017cites this paper
• Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin

  2017cites this paper
• Frontiers in Skeletal Muscle Wasting, Regeneration and Stem Cells

  2016cites this paper
• Chemical-Induced Read-Through at Premature Termination Codons Determined by a Rapid Dual-Fluorescence System Based on S. cerevisiae

  2016cites this paper
• Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives

  2016cites this paper
• Aminoglycoside-stimulated readthrough of premature termination codons in selected genes involved in primary ciliary dyskinesia

  2016cites this paper
• A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.

  2016cites this paper
• Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)

  2016influential citation
• Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases

  2016cites this paper
• Structural hybridization of three aminoglycoside antibiotics yields a potent broad-spectrum bactericide that eludes bacterial resistance enzymes

  2016cites this paper
• Strategies to Correct Nonsense Mutations

  2016cites this paper
• 47 – Cystic Fibrosis

  2016cites this paper
• Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations.

  2016cites this paper
• New and emerging targeted therapies for cystic fibrosis

  2016cites this paper
• Evaluation of Aminoglycoside and Non-Aminoglycoside Compounds for Stop-Codon Readthrough Therapy in Four Lysosomal Storage Diseases

  2015cites this paper
• Translation Re-initiation of PTC Downstream Induced the Escape of Nonsense mRNA from NMD

  2015cites this paper
• Nonsense suppression therapies in ocular genetic diseases

  2015cites this paper
• Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.

  2015cites this paper
• Structural basis for selective targeting of leishmanial ribosomes: aminoglycoside derivatives as promising therapeutics

  2015cites this paper
• Gene therapy for Rett syndrome: prospects and challenges

  2015cites this paper
• Aminoglycoside-Induced Oxidative Stress: Pathways and Protection

  2015cites this paper
• Translational readthrough-promoting drugs enhance pseudoknot-mediated suppression of the stop codon at the Moloney murine leukemia virus gag–pol junction.

  2015cites this paper
• Charakterisierung und experimentelle Therapien eines neuen Mausmodells für das Rett Syndrom

  2015cites this paper
• New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals.

  2015cites this paper
• Usher syndrome: a review of the clinical phenotype, genes and therapeutic strategies

  2015cites this paper
• Models and therapeutic approaches for Niemann-Pick (A/B and C) and other lysosomal storage disorders

  2015cites this paper
• Nonsense-mediated decay in genetic disease: friend or foe?

  2014cites this paper
• Toxicity modulation, resistance enzyme evasion, and A-site X-ray structure of broad-spectrum antibacterial neomycin analogs.

  2014cites this paper
• My Dull Deaf Ears: Four Millennia of Acquired Hearing Loss

  2014cites this paper
• Analysis of carbohydrates and glycoconjugates by matrix‐assisted laser desorption/ionization mass spectrometry: An update for 2009–2010

  2014cites this paper
• Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

  2014cites this paper
• Therapy strategies for Usher syndrome Type 1C in the retina.

  2014cites this paper